Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Equivalents (2020 - 2025)

Apellis Pharmaceuticals has reported Cash & Equivalents over the past 6 years, most recently at $466.2 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $466.2 million for Q4 2025, up 13.35% from a year ago — trailing twelve months through Dec 2025 was $466.2 million (up 13.35% YoY), and the annual figure for FY2025 was $466.2 million, up 13.35%.
  • Cash & Equivalents for Q4 2025 was $466.2 million at Apellis Pharmaceuticals, down from $479.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for APLS hit a ceiling of $765.1 million in Q1 2023 and a floor of $265.4 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $431.9 million (2023), compared with a mean of $459.3 million.
  • Biggest five-year swings in Cash & Equivalents: soared 138.65% in 2022 and later crashed 57.4% in 2024.
  • Apellis Pharmaceuticals' Cash & Equivalents stood at $640.2 million in 2021, then dropped by 13.81% to $551.8 million in 2022, then plummeted by 36.36% to $351.2 million in 2023, then rose by 17.11% to $411.3 million in 2024, then increased by 13.35% to $466.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $466.2 million (Q4 2025), $479.2 million (Q3 2025), and $370.0 million (Q2 2025) per Business Quant data.